Amarin Corporation plc (AMRN)

USD 10.91

(-0.64%)

Market Cap (In USD)

225.94 Million

Revenue (In USD)

306.91 Million

Net Income (In USD)

-59.11 Million

Avg. Volume

90.43 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.45-1.37
PE
-2.73
EPS
-4.0
Beta Value
1.93
ISIN
US0231112063
CUSIP
023111206
CIK
897448
Shares
20709464.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Aaron D. Berg
Employee Count
-
Website
https://www.amarincorp.com
Ipo Date
1993-04-01
Details
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.